Optimizing Timing for Respiratory Syncytial Virus Prevention Interventions for Infants

What is the cost-effectiveness of no intervention, maternal vaccination, and nirsevimab administration during the overall respiratory syncytial virus (RSV) season and for each monthly birth cohort?In this economic evaluation of an estimated monthly birth cohort of 299 277 infants, maternal vaccination was cost-effective compared with no intervention ($19 562 per quality-adjusted life-year), but these results were driven by infants born earlier in the season. Compared with maternal vaccination, nirsevimab was cost-effective only in October and November, at $67 178 and $88 531 per quality-adjusted life-year, respectively.The seasonal nature of RSV and the waning immunogenicity of these interventions suggest that earlier administration could optimize clinical and economic outcomes.

Corresponding Author: Nathorn Chaiyakunapruk, PharmD, PhD, Department of Pharmacotherapy, College of Pharmacy, University of Utah, 30 South 2000 E, Room 4964, Salt Lake City, UT 84112 (nathorn.chaiyakunapruk@utah.edu).

Link to the article in your story

We encourage you to link out to this article in your your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.